NCCN Guidelines Update for Multiple Myeloma.
Anderson KC. J Natl Compr Canc Netw. 2016 May;14(5 Suppl):675-7.

Allogeneic hematopoietic cell transplantation for multiple myeloma in Europe: trends and outcomes over 25 years. A study by the EBMT Chronic Malignancies Working Party.
Sobh M et al. Leukemia. 2016 May 20. doi: 10.1038/leu.2016.101. [Epub ahead of print].

Cost-effectiveness of adding carfilzomib to lenalidomide and dexamethasone in relapsed multiple myelomafrom a US Perspective.
Jakubowiak AJ et al. J Med Econ. 2016 May 25:1-44. [Epub ahead of print].

Cost-effectiveness of bortezomib for multiple myeloma: a systematic review.
Chen W et al. Clinicoecon Outcomes Res. 2016 May 3;8:137-51. doi: 10.2147/CEOR.S104195. eCollection 2016.

Patients with cancer and change of general practice: a Danish population-based cohort study.
Grooss K et al. Br J Gen Pract. 2016 May 23. pii: bjgpJul-2016-66-648-Grooss-FL-P. [Epub ahead of print].

New Drugs Prompt Myeloma Guidelines Update.
[No authors listed]. Cancer Discov. 2016 May 20. [Epub ahead of print].

Three new drugs for multiple myeloma.[No authors listed]. 
Med Lett Drugs Ther. 2016 May 23;58(1495):e70-1.

Treatment of Multiple Myeloma: Finding the Right Combination.
Rosenzweig MA et al. Oncology (Williston Park). 2016 May;30(5). pii: 217052.

Novel Combination Treatments in Multiple Myeloma.
Nooka AK et al. Oncology (Williston Park). 2016 May;30(5). pii: 217049.

Association of Leisure-Time Physical Activity With Risk of 26 Types of Cancer in 1.44 Million Adults.
Moore SC et al. JAMA Intern Med. 2016 May 16. doi: 10.1001/jamainternmed.2016.1548. [Epub ahead of print].

Newer drugs for refractory and relapsed multiple myeloma are effective but costly, review finds.
McCarthy M et al. BMJ. 2016 May 13;353:i2725. doi: 10.1136/bmj.i2725.

Exploring Big Data in Hematological Malignancies: Challenges and Opportunities.
Westin GF et al. Curr Hematol Malig Rep. 2016 May 13. [Epub ahead of print].

Multiple myeloma and persistence of drug resistance in the age of novel drugs (Review).
Krishnan SR et al. Int J Oncol. 2016 May 11. doi: 10.3892/ijo.2016.3516. [Epub ahead of print].

Radioimmunotherapy-based conditioning for hematopoietic stem cell transplantation: Another step forward.
Ali AM et al. Blood Rev. 2016 May 2. pii: S0268-960X(16)30015-7. doi: 10.1016/j.blre.2016.04.007. [Epub ahead of print].

Multiple myeloma and multiple plasmacytomas associated with free gamma heavy chain, free kappa light chain and IgGk paraproteins: an unusual triple gammopathy.
Deighan WI et al. Ann Clin Biochem. 2016 May 10. pii: 0004563216646594. [Epub ahead of print].

Prediction of patients with multiple myeloma eligible for second- or third-line treatment in France.
Rondeau V et al. Ann Hematol. 2016 May 10. [Epub ahead of print].

Lenalidomide (Revlimid): A Thalidomide Analogue in Combination With Dexamethasone For the Treatment of All Patients With Multiple Myeloma.
Cruz MP et al. P T. 2016 May;41(5):308-13.

Pharmaceutical Approval Update.
Choy M et al. P T. 2016 May;41(5):288-333.

Bortezomib improves survival in rare myeloma.
Brower V et al. Lancet Oncol. 2016 May 6. pii: S1470-2045(16)30129-2. doi: 10.1016/S1470-2045(16)30129-2. [Epub ahead of print].

The Rapid Evolution of Novel Therapies in Multiple Myeloma.
Anderson KC et al. J Natl Compr Canc Netw. 2016 May;14(5):493-6.

Addition of Rice Bran Arabinoxylan to Curcumin Therapy May Be of Benefit to Patients With Early-Stage B-Cell Lymphoid Malignancies (Monoclonal Gammopathy of Undetermined Significance, Smoldering Multiple Myeloma, or Stage 0/1 Chronic Lymphocytic Leukemia): A Preliminary Clinical Study.
Golombick T et al. Integr Cancer Ther. 2016 Jun;15(2):183-9. doi: 10.1177/1534735416635742. Epub 2016 May 6.

State-of-the-Art Imaging and Staging of Plasma Cell Dyscrasias.
Amini B et al. Radiol Clin North Am. 2016 May;54(3):581-96. doi: 10.1016/j.rcl.2015.12.008. Epub 2016 Mar 21.

Quadruple Cancers of Non-producing Multiple Myeloma, Cholangiocellular Carcinoma, and Two Different Thyroid Cancers.
Mizutani S et al. Intern Med. 2016;55(9):1183-6. doi: 10.2169/internalmedicine.55.5319. Epub 2016 May 1.

Multiple Myeloma Mortality in Relation to Obesity Among African Americans.
Sonderman JS et al. J Natl Cancer Inst. 2016 May 4;108(10). pii: djw120. doi: 10.1093/jnci/djw120. Print 2016 Oct.

Myeloma imaging: time to move on!
Manasanch EE et al. Leuk Lymphoma. 2016 May 5:1-2. [Epub ahead of print].

Self-Reported Quality of Life and Symptom Burden in Ambulatory Patients With Multiple Myeloma on Disease-Modifying Treatment.
Kiely F et al. Am J Hosp Palliat Care. 2016 May 2. pii: 1049909116646337. [Epub ahead of print].

Innovations in treatment and response evaluation in multiple myeloma.
Wester R et al. Haematologica. 2016 May;101(5):518-20. doi: 10.3324/haematol.2016.142737.

Specialty pharmacy for hematologic malignancies.
Fajardo S et al. Am J Health Syst Pharm. 2016 Jun 1;73(11):797-809. doi: 10.2146/ajhp150749. Epub 2016 Apr 28.

A systematic literature review and network meta-analysis of treatments for patients with untreated multiple myeloma not eligible for stem cell transplantation.
Weisel K et al. Leuk Lymphoma. 2016 Apr 28:1-9. [Epub ahead of print].